Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Published byHelena Kirkegaard Modified over 4 years ago

Similar presentations

Presentation on theme: "Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey."— Presentation transcript:

1 Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey from 1998 to 2003  Daniel Morgensztern, MD, Saiama Waqar, MD, Janakiraman Subramanian, MD, Feng Gao, PhD, Kathryn Trinkaus, PhD, Ramaswamy Govindan, MD  Journal of Thoracic Oncology  Volume 7, Issue 10, Pages (October 2012) DOI: /JTO.0b013e318267d032 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 OS for patients with stages IIIA (1A) and IIIB (1B) according to tumor size. OS, overall survival. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318267d032) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 DSS for patients with stages IIIA (2A) and IIIB (2B) according to tumor size. DSS, disease-specific survival. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318267d032) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey."

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A

Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors  Lorinda Simms, MSc, P Stat, Helen Barraclough, MSc, Ramaswamy.

Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors  Lorinda Simms, MSc, P Stat, Helen Barraclough, MSc, Ramaswamy.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 
Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC
Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non–Small Cell Lung Cancer  Patrick Wald,

Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non–Small Cell Lung Cancer  Patrick Wald,
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
Hedgehog Signaling Pathway and Lung Cancer

Hedgehog Signaling Pathway and Lung Cancer

Similar presentations

Ads by Google